MarketPulse

ophthalmology

5 articles
The Motley FoolThe Motley Fool··Jonathan Ponciano

EyePoint Pharmaceuticals Attracts $20M Strategic Investment Amid 93% Annual Surge

Parkman Healthcare Partners invests $20M in EyePoint Pharmaceuticals as shares surge 93% annually ahead of mid-2026 Phase 3 data for retinal disease treatment DURAVYU.
CVSDXCMEYPTPODDbiotechPhase 3 trials
BenzingaBenzinga··Bamboo Works

VivaVision Races to Complete Hong Kong IPO as Cash Runway Narrows

VivaVision Biotech rushes Hong Kong IPO as cash reserves dwindle to $5.2 million against $6.3 million quarterly burn rate. Two late-stage eye disease candidates drive investor appeal.
AMGNABTcash burnclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Eyepoint, Inc.

EyePoint Pharmaceuticals Names Veteran Ophthalmology Executive Campbell as CCO

EyePoint Pharmaceuticals appoints Michael Campbell as Chief Commercial Officer. The ophthalmology veteran brings 30+ years of experience to lead commercial strategy for DURAVYU ahead of 2026 clinical data.
EYPTPhase 3 clinical trialophthalmology
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis Names Veterans Legal Executive as CLO Amid Clinical Pipeline Expansion

Oculis appoints seasoned legal executive Katie Kazem as Chief Legal Officer to strengthen governance as it advances clinical pipeline with late-stage therapeutic candidates.
OCSOCSAWsecurities lawclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Oculis Names Experienced Life Sciences Attorney as Chief Legal Officer

Oculis appoints Katie Kazem as Chief Legal Officer. She brings 15+ years of life sciences legal expertise to support the company's three late-stage clinical programs.
OCSOCSAWsecurities lawclinical trials